Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving irinotecan together with cetuximab may
kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan together with cetuximab
works in treating patients with metastatic breast cancer.